RecruitingPHASE1, PHASE2NCT06828042

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University Third Hospital
Intervention
anti-CD19 CAR T cell therapy(biological)
Enrollment
9 enrolled
Eligibility
18-80 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06828042 on ClinicalTrials.gov

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

← Back to all trials